While more biosimilars gained regulatory approval 2017 and neared their entry into the US marketplace, physician acceptance of these products proved to be a challenge.
While more biosimilars gained regulatory approval in 2017 and neared their entry into the US marketplace, physician acceptance of these products proved to be a challenge.
A survey of community-based US oncologists and hematologists found that:
The researchers in this study concluded that significant gaps in education pose a barrier to physicians’ acceptance of oncology biosimilars, and 2 posters presented at the American College of Rheumatology’s 2017 meeting in San Diego, California, pointed to similar gaps in US rheumatologists’ knowledge.
In the first, a survey of practicing rheumatologists, approximately 60% of respondents were unlikely to switch from a reference biologic to a biosimilar in patients who were responding well to their current therapy. Additionally, 21% of respondents were extremely likely or likely to switch to a biosimilar if the patient was failing to respond well to the originator.
In the second survey, in which respondents were rheumatologists or rheumatology practice managers, only 51% understood the concept of interchangeability, only 40% believed that biosimilars had equivalent safety and efficacy to their references, and 20% said they would not prescribe a biosimilar.
The results of such surveys led Stacie Phan, MBA, MS, president of the Biosimilars Forum, to write in a contributor article at The Center for Biosimilars® that “Researchers who worked on both surveys concluded that physicians’ lack of knowledge about biosimilars and their ambivalence about prescribing these drugs present a significant barrier for building a robust biosimilars market in the United States. This barrier has implications not only for patients suffering from RA, but also from psoriatic arthritis, Crohn disease, ulcerative colitis, and various types of cancer—including breast cancer, metastatic colorectal cancer, non-squamous non-small cell lung cancer, and glioblastoma.”
Phan called for physicians to educate themselves about these therapies for the good of their patients: “We need a medical community that is fully educated about the benefits of biosimilars so that the promise of these drugs can be fully realized in the United States,” she said.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.